The morphological and immunochemical features of nephropathies in multiple myeloma and severe renal failure


Cite item

Full Text

Abstract

AIM: To study the pathomorphology of kidneys in patients with multiple myeloma (MM) and severe renal failure (RF) and to compare the results of morphological, immunohistochemical, and electron microscopic examinations of nephrobiopsy specimens with the pattern of monoclonal secretion and the type of proteinuria and paraproteinuria/MATERIAL AND METHODS: A study group comprised 25 patients with MM and severe RF; 22 of them underwent programmed hemodialysis. Immunochemical study of serum and urine proteins, renal puncture biopsy with light, immunofluorescence and electron microscopy examination of its specimens were performed in all the patients/RESULTS: Cast nephropathy (CN) is the most common type of renal impairment in patients with MM and severe RF. CN concurrent with monoclonal immunoglobulin deposition disease was identified in 32% of cases. In the mixed lesion, it is CN that is a determinant in the development of acute and chronic RF. Rare variants of nephropathies as fibrillary glomerulonephritis, immunotactoid nephropathy, and crystalline histiocytosis were found in 16% of cases. In most cases, severe RF in MM develops in case of low monoclonal secretion. However, there are a larger number of secreted and excreted monoclonal light chains in CN than in other variants of kidney lesion. Urinary paraprotein G excretion suggests that the glomerular filter is damaged. Degenerative changes in the podocytes and a reduction in their small processes were detected in the majority of cases. In glomerular or mixed proteinuria, there were also unorganized and organized deposits in the glomerular basement membrane/CONCLUSION: The pattern of nephropathy does not determine a renal response after chemotherapy. The reversibility of CN in MM depends on the magnitude of interstitial fibrosis and podocyte changes. The pronounced changes in the podocytes as a reduction in their small processes serves as a poor sign in achieving renal responses following chemotherapy.

About the authors

I G Rekhtina

Гематологический научный центр Министерства здравоохранения России

Email: rekhtina@blood.ru

E P Golitsina

Первый МГМУ им. И.М. Сеченова

Email: e.p.golicina@mail.ru

E Iu Varlamova

Гематологический научный центр Министерства здравоохранения России

Email: gammopat@blood.ru

V A Varshavskiĭ

Первый МГМУ им. И.М. Сеченова

Email: Vavarsh@mmscience.ru

A A Kireeva

Гематологический научный центр Министерства здравоохранения России

L S Biriukova

Гематологический научный центр Министерства здравоохранения России

Email: birjurova@blood.ru

V G Savchenko

Гематологический научный центр Министерства здравоохранения России

References

  1. Paueksakon P., Revelo M., Horn R. еt al. Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003; 42 (1): 87-95.
  2. Pirani C.L., Silva F.G., Appel G.B. Interstitial disease in multiple myeloma and other non renal neoplasias. In: Contran R.S., Brenner B.M., Stein J.H. (ed). Tubulo-interstitial nephropathies. London: Churchill Livingstine 1983: 208-221.
  3. Qian Q., Leung N., Theis J.D. et al. Coexistence of myeloma cast nephropathy, light chain deposition disease and nonamyloid fibrils in a patient with multiple myeloma. Am J Kidney Dis 2010; 56: 971-976.
  4. Jabur W.L., Saeed H.M., Abdulla K. Plasma cell dyscrasia; LCDD vs immunotactoid glomerulopathy. Saidi J Kidney Dis Transplant 2008; 19: 802-805.
  5. Lin J., Markowitz G.S., Valeri A.M. et al. Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol 2001; 12: 1482-1492.
  6. Gokden N., Cetin N., Colakoglu N. et al. Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy. Ultrastruct Pathol 2007; 31 (2): 141-149.
  7. Tsakiris D.J., Stel V.S., Finne P. et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERA-EDTA Registry study. Nephrol Dial Transplant 2010; 25: 1200-1206.
  8. Pozzi C., Amigo M., Fogazzi S. et al. Light chain deposition disease with renal involvement: clinical characteristics and prognosis factors. Am J Kidney Dis 2003; 42: 1154-1163.
  9. Lebeau A., Zeindl-Eberhart E., Muller E.C. et al. Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of literature. Blood 2002; 5: 1817-1827.
  10. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
  11. Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potencial of Bence Jones proteins. N Engl J Med 1991; 324: 1845-1851.
  12. Rostagno A., Vidal R., Kaplan B. pH-dependent fibrillogenesis of a V kappa III Bence Jones protein. Br J Haematol 1999; 107 (4): 835-843.
  13. Huang Z.Q., Sanders P.W. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Inves. 1995; 73 (6): 810-817.
  14. Khamlichi A.A., Rocca A., Touchard G. et al. Role of light chain variable region in myeloma with light chain deposition disease evidence from an experimental model. Blood 1995; 86 (10): 3655-3659.
  15. Sanders P.W., Herrera G.A., Chen A. et al. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988; 82: 2086-2096.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies